News:

 

November 25, 2011

REPLICor to disclose new mechanism of action data and interim REP 9AC and REP 9AC’ clinical efficacy data in patients with chronic hepatitis B at the 2011 HEPDART meeting.

   
October 27, 2011

REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD 2011)

   
March 30, 2011

REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 46th meeting of the European Association for the Study of the Liver (EASL 2011)

   
February 17, 2011

REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011)

   
October 28, 2010 REPLICor to disclose interim REP 9AC clinical efficacy data in patients with chronic hepatitis B at the 61st annual meeting of the AASLD in Boston, U.S.A.
   
March 18, 2010 REPLICor to present interim REP 9AC clinical efficacy data at the 20th annual meeting of the APASL in Beijing, China
   
December 8, 2009 Dr. Allison Jilbert presents preclinical efficacy data for REP 9AC in DHBV infected Pekin ducks
   
December 2, 2009 REPLICor publishes data on the activity and safety of amphipathic DNA polymers (APs) in cytomegalovirus infection
   
April 23, 2009 Publication of REPLICor’s first in class HCV entry inhibitor based on its amphipathic DNA polymer technology
   
April 16, 2009 REPLICor publishes data on mechanism of action and pre-clinical efficacy of amphipathic DNA polymers (APs) in HCV infection
   
March 31, 2009 REPLICor to present preclinical data showing a curative response to hepatitis B infection with its drug at the 1st Annual Girindus Leaders in Oligonucletides Meeting
   
March, 2009 REPLICor initiates dosing of human patients with its drug
   
February, 2009 REPLICor receives IRB approval to conduct a phase I / II trial to test the safety and efficacy of its drug in patients with chronic hepatitis B and hepatitis C
   
April 13, 2008 REPLICor to Present at the 21st International Conference on Antiviral Research
   

January 10, 2008

REPLICor : Une Entreprise Audacieuse (French only)
   
December 06, 2007 REPLICor’s Data on REP 9C / REP 9AC Presented at the HEPDART Meeting
   
December 04, 2007 REPLICor Recognized as a Top 10 Life Sciences Companies in Canada
   
November 30, 2007 REPLICor Receives Notice of Allowance for Key Patent Application
   
September 16, 2007 REPLICor to Present at the RSC Virus Molecular Interactions Conference
   
September 10, 2007 REPLICor Collaborators to Present at the HBV Meeting
   
September 08, 2007 REPLICor to Present at  the 14th Symposium of Hepatitis C and Related Viruses
   
April 23, 2007 REPLICor to Present at 20th International Conference on Antiviral Research
   
February 28, 2007 REPLICor to Present at the 3rd Annual Viral Hepatitis in Drug Discovery & Development World Summit
   
October 24, 2006 REPLICor to disclose results of its first-in-class drugs against hepatitis C
   
September 19, 2006 REPLICor's Drug Activity in the Metabolic Syndrome
   
June 21, 2006 REPLICor Presenting at Metabolic Diseases Summit
   
May 05, 2006 REPLICor  to present at the American Society for Microbiology General Meeting 2006
   
May 05, 2006 REPLICor  to present at the 19th International Conference on Antiviral Research
   
May 05, 2006 Oligos Enable New Classes of Therapeutics
   
April 28, 2006 REPLICor to present at TIDES 2006
   
April 22, 2006 REPLICor, NIAID identify potential anti-prion therapeutic
   
April 5, 2006 REPLICor’s Antiviral Drug Is Active against H5N1 Avian Flu
   
November 1st, 2005 REPLICor’s Antiviral Drug Promises Potent Activity against H5N1 Avian Flu
   
April 11, 2005 REPLICor Describes its Corporate Strategies in the Biomed Business Journal
   
March 30, 2005 REPLICor to Disclose Unique Broad Spectrum Antiviral Drug
   
November 10, 2004 Girindus to Produce Antiviral Treatment for Canada's Replicor
   
November 8, 2004 REPLICor Named One of Canada’s Top Ten Life Science Companies